Home > Insider Trading > Filing (0000899243-23-000973)

Filing Details

Accession Number:: 0000899243-23-000973
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-01-05 16:06:47
Reporting Period:: 2023-01-03

Accepted Time:: 2023-01-05 16:06:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1745999	Beam Therapeutics Inc.	BEAM	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786322	Giuseppe Ciaramella	C/O Beam Therapeutics Inc., 238 Main Street Cambridge MA 02142	President & Cso	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-01-03	9,106	$0.67	105,068	No	4	M	Direct
Common Stock	Acquisiton	2023-01-03	4,326	$4.22	109,394	No	4	M	Direct
Common Stock	Acquisiton	2023-01-03	40,297	$0.67	149,691	No	4	M	Direct
Common Stock	Disposition	2023-01-03	37,525	$37.14	112,166	No	4	S	Direct
Common Stock	Disposition	2023-01-03	13,704	$37.99	98,462	No	4	S	Direct
Common Stock	Disposition	2023-01-03	1,900	$39.07	96,562	No	4	S	Direct
Common Stock	Disposition	2023-01-03	600	$39.94	95,962	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-01-03	9,106	$0.00	9,106	$0.67
Common Stock	Stock Option (Right to Buy)	Disposition	2023-01-03	4,326	$0.00	4,326	$4.22
Common Stock	Stock Option (Right to Buy)	Disposition	2023-01-03	40,297	$0.00	40,297	$0.67

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2028-05-08	No	4	M	Direct
0	2029-02-13	No	4	M	Direct
150,905	2028-05-08	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.66 to $37.65, inclusive. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.66 to $38.48, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.82 to $39.75, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The option award vested upon the achievement of a closing price hurdle following BEAM's initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.
The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.